| Species |
Human |
| Protein Construction |
Her4/ErbB4 (Gln26-Pro651)
Accession # Q15303-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Her4/ErbB4 hFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Biotinylated Human NRG1 Beta 1, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
96.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 100-120 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ErbB4, a member of the EGF receptor family, plays a variety of roles in physiological and pathological states. Genetic studies have indicated a link between ErbB4 and type 2 diabetes and obesity. ErbB4 may play an important role in glucose homeostasis and lipogenesis. ErbB4 deficiency-related obesity and adipose tissue inflammation may contribute to the development of MetS. |
| Synonyms |
p180erbB4; 4ICD; E4ICD; HER4; ErbB4; MGC138404; ALS19 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
